Aurobindo Pharma enterprise value

·Pharma & HealthChart ›
MultiplesEnterprise valuePer share
Share price at each year-end
Tap a line for its trendCurrentlast 12MFY26Mar 2026FY25Mar 2025FY24Mar 2024FY23Mar 2023FY22 and earlierAlpha Plus
95,530————
FY22 and earlierEvery year the company has filed comes with Alpha Plus.
7,9397,9395,5693,4444,547
−8.2−8.2−6.48.012.0
7,6767,6767,9426,3154,862
95,259————
−262−2622,3732,871314
₹1,640.14————
45,55945,55940,58936,16631,713
16.8%16.8%19.6%17.5%15.3%
0.08×————
2.73×————
13.44×————
18.23×————
39.34×————
Reference items — trailing FY values
34,93533,65331,72429,00224,855
7,0856,8466,5835,8433,719
5,2265,0684,9334,3212,474
—5,5263,9252,4352,387
2,4222,4221,405−1,127−334
—2,3131,275−1,196−363
—3,1052,5203,5622,720
Open the chart

From the company's filings with NSE and BSE (Ind-AS), consolidated. For information only, not investment advice.

AUROPHARMA₹1,644.80

Aurobindo Pharma Ltd.

· Pharma & Health
₹ CrorePeersSUNPHARMADRREDDYCIPLAFORTISLUPINALKEMLAURUSLABSMANKINDMcap ₹95,530 Cr
HighlightsEnterprise ValueMultiplesPer ShareAnnuals · FY-end closes
In ₹ Crore except Per Share
12 Months Ending
FY23
31/03/2023
FY24
31/03/2024
FY25
31/03/2025
FY26
31/03/2026
Current/LTM
TTM · last close
Market Capitalization————95,530.0
- Cash, Equiv & ST Investments4,547.33,444.15,569.07,938.67,938.6
+ Minority Interest12.08.0-6.4-8.2-8.2
+ Total Debt4,861.56,315.27,941.77,676.27,676.2
Enterprise Value————95,259.4
Net Debt (memo)314.22,871.22,372.7-262.4-262.4
EV per Share————1,640.14
Total Capital31,713.436,166.040,588.645,559.045,559.0
Total Debt/Total Capital15.3317.4619.5716.8516.85
Total Debt/EV————0.08
EV/Sales————2.73
EV/EBITDA————13.44
EV/EBIT————18.23
EV/Free Cash Flow————39.34
Reference Items — Trailing FY Values
Sales24,855.429,001.931,723.733,653.134,935.3
EBITDA3,718.65,843.06,582.86,845.77,085.3
EBIT2,474.14,321.34,933.45,067.55,226.0
Operating Cash Flow2,386.82,434.53,924.65,526.4—
Free Cash Flow-333.7-1,127.01,405.12,421.72,421.7
FCFF (free cash flow to the firm)-362.7-1,196.01,274.62,313.4—
Capital Expenditure2,720.43,561.52,519.63,104.7—
Market Cap/EV/multiples pair each (split/bonus-adjusted) FY-end close with the latest filed share count; Current column uses the last close. Market Capitalization is a market-level figure — identical across Consolidated/Standalone (the accounting rows below differ). No consensus estimates → no Est columns. Click any row to chart it.
« ‹ › »Latest: FY26 · ConsolidatedFA Financial Analysis · alphave
Data & compliance. Descriptive financial information from official NSE/BSE filings — for information and education only, not investment advice, a recommendation, or a valuation. Standalone = parent entity; consolidated includes subsidiaries. Historical multiples pair each fiscal year's filed figures with that FY-end market close; the Current column uses the last close with the latest filed annuals. Figures are cross-verified via accounting identities and NSE×BSE agreement — XBRL cross-verified ✓ 95%.